About MiRagen
MiRagen is a publicly listed company based in Boulder (United States) founded in 2007 by Sanjoy Mahanty, William Marshall, and Bruce Booth. MicroRNA-based therapeutics are developed for treating multiple diseases. MiRagen has raised $111.29 million across 19 funding rounds from investors including Fidelity Investments, Citadel and Atlas Venture. The company has 92 employees. MiRagen has completed 2 acquisitions, including Signal Genetics and Viridian Bio. MiRagen offers products and services including TED Programs and FcRn Portfolio. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is MIRAGEN THERAPEUTICS, INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
MiRagen was established in 2007 in Boulder, United States, within the biotechnology sector. MicroRNA-based therapeutic solutions are created for addressing various diseases, including haematological malignancies, neurodegeneration, and ischemia. The drug pipeline features candidates like MRG-106, MRG-107, and MRG-110. Co-founders such as Sanjoy Mahanty, William Marshall, and Bruce Booth contribute to leadership in these operations.
- Headquarters Boulder, United States
- Employees 92
- Founders Sanjoy Mahanty, William Marshall, Bruce Booth
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website miragen.com
- Social LinkedIn X
- Legal Name Miragen Therapeutics, Inc.
- Total Equity Funding$111.29M (USD)
in 19 rounds
- Latest Funding Round$91M (USD), Post-IPO
Oct 2020
- InvestorsFidelity Investments
& 20 more
- Employee Count92
- Investments & AcquisitionsSignal Genetics
& 1 more
Products & Services of MiRagen
MiRagen offers a comprehensive portfolio of products and services, including TED Programs and FcRn Portfolio.
Develops treatments for thyroid eye disease through antibody engineering.
Focuses on therapies for autoimmune conditions via optimized antibodies.
Funding Insights of MiRagen
MiRagen has successfully raised a total of $111.29M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $91 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $111.29M
- Total Rounds 19
- Last Round Post-IPO — $91M
- First Round $1M
(Mar 2008)
- Investors Count 21
Latest 10 of 19 funding rounds of MiRagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $91M | Post-IPO | – | – | |
| Oct 2019 | $1.5M | Post-IPO | – | – | – |
| Nov 2017 | $172,294 | Series C | – | – | – |
| Feb 2017 | $40.7M | Post-IPO | – | – | |
| Nov 2016 | $40M | Series C | – | – | |
| Nov 2015 | $41M | Post-IPO | – | – | |
| Feb 2015 | $8.5M | Post-IPO | – | – | – |
| Feb 2015 | $8.5M | Series B | – | – | |
| Jun 2014 | $7M | Series B | – | – | |
| Jun 2014 | $13M | Post-IPO | – | – | – |
21 investors in total: 21 institutional.
Investors in MiRagen
MiRagen has secured backing from 21 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Citadel and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Private equity and hedge fund investments in healthcare are managed. | ally-bridge.com | Hong Kong, China | ||
Venture capital is provided to healthcare startups by Commodore Capital. | commodorecapital.com | New York, United States | ||
Ridgeback Capital is focused on healthcare and life science investments. | ridgebackcap.com | New York, United States | ||
Brace Pharma Capital is focused on investing in innovative therapies. | bracepharma.com | Atlanta, United States | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Venture capital is offered by Boulder Ventures for innovative companies. | boulderventures.com | Boulder, United States |
Investor details for MiRagen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MiRagen
75 people are tracked at MiRagen (47 in leadership, 14 in board & advisors, 14 in team); the tracked headcount is 92.
| Name | Role | Group |
|---|---|---|
Sanjoy Mahanty | Co-Founder | Leadership |
William Marshall | Co-Founder | Leadership |
Bruce Booth | Co-Founder & Chairman | Leadership |
Shan Wu | Chief Business Officer | Leadership |
Melissa Manno | Chief Human Resources Officer | Leadership |
Richard Manning | Senior Director Patient Services | Leadership |
Nirali Sampat | Director, Business Development & Strategic Alliances | Leadership |
Craig Moquin | Director, Device Development & Manufacturing | Leadership |
Alyssa Yenikomshian | Director, R&d Counsel | Leadership |
Jason A. Leverone | Chief Financial Officer | Leadership |
Rachel Kaplan Newell | Associate Director, Research | Leadership |
Mark Howansky | Vice President Of Device Development And Commercialization | Leadership |
Steve Graunke | Director - Process Development | Leadership |
Partha Ghosh | Director Regulatory CMC | Leadership |
Rochelle Summerfelt | Vice President, Clinical Development | Leadership |
Shula Pollard | Sr Director, Scientific Communications | Leadership |
Shane Bouchard | Executive Director, Business Development & Strategic Alliances | Leadership |
Sean Nugent | Associate Director, Drug Development | Leadership |
Laura Epelbaum | Director Clinical Operations | Leadership |
Sarah Jane Constantine | Senior Vice President, Clinical Operations | Leadership |
55 more people are available in the full profile.
Complete people profiles for MiRagen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MiRagen
MiRagen has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Signal Genetics and Viridian Bio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Providing aid in translating basic science research into products | viridianbio.com | Philadelphia, United States | 2019 | Oct 2020 | •••• | |
Microarray-based prognostic tests are provided for disease risk assessment. | signalgenetics.com | Carlsbad, United States | 2010 | Oct 2016 | •••• |
Complete acquisition details for MiRagen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of MiRagen
6 dated milestones of MiRagen across 13 years, from founding to its latest funding, stage changes and deals.
- Founded MiRagen is founded.
- Funding First funding round of $1.0M.
- Acquisition Acquires Signal Genetics.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $91.0M.
- Acquisition Acquires Viridian Bio.
Competitors of MiRagen
MiRagen has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of MiRagen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as MiRagen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Miragen
Complete news archive for MiRagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MiRagen
MiRagen was founded in 2007 and raised its 1st funding round 1 year after it was founded.
MiRagen is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
MiRagen is a funded company, having raised a total of $111.29M across 19 funding rounds to date. The company's 1st funding round was a Post-IPO of $13M, raised on Mar 2008.
MiRagen has 92 employees.
MiRagen was established in 2007 in Boulder, United States, within the biotechnology sector. MicroRNA-based therapeutic solutions are created for addressing various diseases, including haematological malignancies, neurodegeneration, and ischemia. The drug pipeline features candidates like MRG-106, MRG-107, and MRG-110. Co-founders such as Sanjoy Mahanty, William Marshall, and Bruce Booth contribute to leadership in these operations.
MiRagen offers TED Programs and FcRn Portfolio.
MiRagen has made 2 acquisitions, including Signal Genetics, and Viridian Bio.
MiRagen has 21 investors. Key investors include Fidelity Investments, Citadel, Atlas Venture, Perceptive Advisors, and Fairmount Funds Management.
MiRagen operates through Miragen Therapeutics, Inc..